Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking Beyond and

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Feb 15

PMID 35159349

Authors

David Samuel

Alexandra Diaz-Barbe

Andre Pinto

Matthew Schlumbrecht

Sophia George

Affiliations

Soon will be listed here.

Abstract

Besides and , several other inheritable mutations have been identified that increase ovarian cancer risk. Surgical excision of the fallopian tubes and ovaries reduces ovarian cancer risk, but for some non- hereditary ovarian cancer mutations the benefit of this intervention is unclear. The fallopian tubes of women with hereditary ovarian cancer mutations provide many insights into the early events of carcinogenesis and process of malignant transformation. Here we review cancer pathogenesis in hereditary cases of ovarian cancer, the occurrence of pre-invasive lesions and occult carcinoma in mutation carriers and their clinical management.

Citing Articles

The role of MUC16 in tumor biology and tumor immunology in ovarian cancer.

Yang N, Zhou X, Gong Y, Deng Z BMC Cancer. 2025; 25(1):294.

PMID: 39972413 PMC: 11837316. DOI: 10.1186/s12885-025-13461-0.

Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a mutation.

Huang W, Meng H, Xu Y, Huang L, Lou G Oncol Lett. 2024; 29(2):67.

PMID: 39619421 PMC: 11605280. DOI: 10.3892/ol.2024.14813.

Serous Tubal Intraepithelial Carcinoma (STIC): A Review of the Literature on the Incidence at the Time of Prophylactic Surgery.

Luvero D, Angioli R, Notaro E, Plotti F, Terranova C, Angioli A Diagnostics (Basel). 2024; 14(22).

PMID: 39594243 PMC: 11592719. DOI: 10.3390/diagnostics14222577.

RNA-binding protein THUMPD2 inhibits proliferation and promotes metastasis in epithelial ovarian cancer.

Hua M, Chen Y, Jia M, Lv W, Xu Y, Zhang Y Heliyon. 2024; 10(13):e33201.

PMID: 39071668 PMC: 11279259. DOI: 10.1016/j.heliyon.2024.e33201.

Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer.

Chaudhry Z, Boyadzhyan A, Sasaninia K, Rai V Antibodies (Basel). 2024; 13(2).

PMID: 38920970 PMC: 11200483. DOI: 10.3390/antib13020046.

References

Lai T, Kessel B, Ahn H, Terada K . Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer. J Gynecol Oncol. 2016; 27(4):e41. PMC: 4864517. DOI: 10.3802/jgo.2016.27.e41. View

Mingels M, Roelofsen T, van der Laak J, de Hullu J, van Ham M, Massuger L . Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls. Gynecol Oncol. 2012; 127(1):88-93. DOI: 10.1016/j.ygyno.2012.06.015. View

Kuhn E, Kurman R, Vang R, Sehdev A, Han G, Soslow R . TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol. 2011; 226(3):421-6. PMC: 4782784. DOI: 10.1002/path.3023. View

Gonzalez-Martin A, Pothuri B, Vergote I, Christensen R, Graybill W, Mirza M . Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25):2391-2402. DOI: 10.1056/NEJMoa1910962. View

Schoolmeester J, Moyer A, Goodenberger M, Keeney G, Carter J, Bakkum-Gamez J . Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2. Hum Pathol. 2017; 70:14-26. DOI: 10.1016/j.humpath.2017.06.018. View

Potapova A, Hoffman A, Godwin A, Al-Saleem T, Cairns P . Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res. 2008; 68(4):998-1002. DOI: 10.1158/0008-5472.CAN-07-2418. View

Baandrup L, Kjaer S, Olsen J, Dehlendorff C, Friis S . Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann Oncol. 2014; 26(4):787-792. DOI: 10.1093/annonc/mdu578. View

Sowamber R, Chehade R, Bitar M, Dodds L, Milea A, Slomovitz B . CCAAT/enhancer binding protein delta (C/EBPδ) demonstrates a dichotomous role in tumour initiation and promotion of epithelial carcinoma. EBioMedicine. 2019; 44:261-274. PMC: 6603855. DOI: 10.1016/j.ebiom.2019.05.002. View

Tung N, Domchek S, Stadler Z, Nathanson K, Couch F, Garber J . Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016; 13(9):581-8. PMC: 5513673. DOI: 10.1038/nrclinonc.2016.90. View

10.

Carlson J, Jarboe E, Kindelberger D, Nucci M, Hirsch M, Crum C . Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int J Gynecol Pathol. 2010; 29(4):310-4. DOI: 10.1097/PGP.0b013e3181c713a8. View

11.

Choi Y, Terry M, Daly M, MacInnis R, Hopper J, Colonna S . Association of Risk-Reducing Salpingo-Oophorectomy With Breast Cancer Risk in Women With BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol. 2021; 7(4):585-592. PMC: 7907985. DOI: 10.1001/jamaoncol.2020.7995. View

12.

Schrijver L, Olsson H, Phillips K, Terry M, Goldgar D, Kast K . Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectr. 2019; 2(2):pky023. PMC: 6649757. DOI: 10.1093/jncics/pky023. View

13.

. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24(7):728-753. DOI: 10.1097/GME.0000000000000921. View

14.

Finch A, Shaw P, Rosen B, Murphy J, Narod S, Colgan T . Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005; 100(1):58-64. DOI: 10.1016/j.ygyno.2005.06.065. View

15.

Bono M, Fanale D, Incorvaia L, Cancelliere D, Fiorino A, Calo V . Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge. ESMO Open. 2021; 6(4):100235. PMC: 8358413. DOI: 10.1016/j.esmoop.2021.100235. View

16.

Trabert B, Ness R, Lo-Ciganic W, Murphy M, Goode E, Poole E . Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst. 2014; 106(2):djt431. PMC: 3924755. DOI: 10.1093/jnci/djt431. View

17.

Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso M, Gilbert F . Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol. 2016; 27(suppl 5):v103-v110. DOI: 10.1093/annonc/mdw327. View

18.

Lu H, Li S, Black M, Lee S, Hoiness R, Wu S . Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing. JAMA Oncol. 2018; 5(1):51-57. PMC: 6439764. DOI: 10.1001/jamaoncol.2018.2956. View

19.

Press J, Wurz K, Norquist B, Lee M, Pennil C, Garcia R . Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers. Neoplasia. 2010; 12(12):993-1002. PMC: 3003134. DOI: 10.1593/neo.101044. View

20.

Lilyquist J, LaDuca H, Polley E, Davis B, Shimelis H, Hu C . Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol. 2017; 147(2):375-380. PMC: 5801741. DOI: 10.1016/j.ygyno.2017.08.030. View